

Special Issue

Drug Discovery of Antiprotozoal Agents

Message from the Guest Editor

Protozoan diseases continue to be a serious worldwide health problem, causing serious social and economic impacts, especially in developing countries. Protozooses such as malaria, leishmaniasis, trypanosomiasis, toxoplasmosis, trichomoniasis, giardiasis and amoebiasis are responsible for high mortality and morbidity rates, with the potential to affect more than 1 billion people worldwide. In this special Issue, authors are invited to submit review and original articles related to the recent research in drug design and discovery, synthesis, and pharmacological properties (in vitro and in vivo) of natural products and/or synthetic compounds that have the potential to become drug candidates for protozoan diseases. As well as presenting the latest advances in the search for pharmacological targets for protozoan diseases, with the aim to provide researchers with the most up-to-date information in this field.

Guest Editor

Prof. Dr. Francisco Jaime Bezerra Mendonça Júnior
Laboratory of Synthesis and Drug Delivery, State University of Paraíba,
João Pessoa 58020-540, PB, Brazil

Deadline for manuscript submissions

closed (25 October 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/153762

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)